Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
21 dec 2007 - 08:10
Statutaire naam
Crucell N.V.
Titel
Aeras and Crucell Announce Start of a Tuberculosis Vaccine Clinical Trial in the United States. Aeras commits a further USD 5 million to the development of the tuberculosis vaccine
Bericht
Leiden, The Netherlands, December 21, 2007 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it will receive up to USD 5 million from Rockville, Maryland-headquartered Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac®- and PER.C6®-based tuberculosis vaccine.
Crucell and Aeras also announced the launch of a new Phase I BCG-Ad35 prime boost clinical trial of the unique AdVac®-based tuberculosis vaccine, weeks sooner than expected. The trial will be conducted in St. Louis, Missouri, USA under the direction of Dr. Daniel F. Hoft at the Saint Louis University Center for Vaccine Development.
“We are very proud that Crucell’s technologies are playing a key role in the search and development of a much-needed TB vaccine,” said Dr. Jaap Goudsmit, Chief Scientific Officer at Crucell. “We also feel honored to collaborate with Aeras on this important mission.”
Aeras and Crucell began jointly developing this vaccine candidate, called AERAS-402, in 2004 using Crucell’s AdVac® vaccine technology and PER.C6® manufacturing technology. A Phase I clinical trial launched in October 2006 in the United States, indicates that the vaccine candidate is safe in healthy adults in the US. A second study in progress in healthy adults in South Africa appears to be showing safety, tolerability and immunogenicity of AERAS-402.
The main parameters under examination in the St. Louis study will be the immunogenicity and safety of BCG prime followed by two AERAS-402 boost doses administered at three to six month intervals after BCG in healthy adults.
The trial will be conducted as double-blind, randomized, placebo-controlled study in 32 healthy adult volunteers.
Datum laatste update: 01 januari 2026